294 results on '"Toppmeyer, Deborah"'
Search Results
2. Clinical efficacy of PARP inhibitors in breast cancer
3. Adapting and implementing breast cancer follow-up in primary care: protocol for a mixed methods hybrid type 1 effectiveness-implementation cluster randomized study
4. Long-Term Clinical and Cosmetic Outcomes of Once-Daily Accelerated Partial Breast Irradiation in Early Breast Cancer
5. Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy
6. Uveitis, a rare but important complication of adjuvant zoledronic acid for early-stage breast cancer
7. A Pharmacogenetic Prediction Model of Progression‐Free Survival in Breast Cancer using Genome‐Wide Genotyping Data from CALGB 40502 (Alliance)
8. Randomized trial promoting cancer genetic risk assessment when genetic counseling cost removed: 1-year follow-up
9. HLA inherence as a potential parameter in checkpoint inhibitor-associated autoimmune adverse event assessment
10. Utilization of Hypofractionated Whole-Breast Radiotherapy With Concurrent Anti-Human Epidermal Growth Factor Receptor 2 (HER2) Therapy
11. 5-Year Update of a Multi-Institution, Prospective Phase 2 Hypofractionated Postmastectomy Radiation Therapy Trial
12. 5-Year Results of a Prospective Phase 2 Trial Evaluating 3-Week Hypofractionated Whole Breast Radiation Therapy Inclusive of a Sequential Boost
13. Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance)
14. Decisional conflict among breast cancer patients considering contralateral prophylactic mastectomy
15. Identifying Mediators of Intervention Effects Within a Randomized Controlled Trial to Motivate Cancer Genetic Risk Assessment Among Breast and Ovarian Cancer Survivors
16. LONG TERM CLINICAL AND COSMETIC OUTCOMES OF ONCE DAILY APBI IN EARLY BREAST CANCER
17. P550: Genetic counselors’ perspectives on shifting emphasis to post-test counseling following germline genetic testing in cancer care
18. Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory Analysis
19. Abstract P5-02-47: Quantitative proteomic analysis of plasma exosomes from patients with advanced hormone receptor-positive/HER2-negative breast cancer receiving palbociclib and tamoxifen
20. Abstract P4-01-38: A single arm phase II trial of Palbociclib in combination with Tamoxifen as first line therapy for metastatic hormone receptor positive breast cancer
21. Abstract P5-07-08: Evaluating the risk of cardiotoxicity associated with concurrent trastuzumab emtansine (TDM1) and radiation therapy in patients with early-stage HER2 positive breast cancer
22. Improving Uptake of Cancer Genetic Risk Assessment in a Remote Tailored Risk Communication and Navigation Intervention: Large Effect Size but Room to Grow
23. Understanding cancer genetic risk assessment motivations in a remote tailored risk communication and navigation intervention randomized controlled trial
24. Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance)
25. Phase I Trial Design and Methodology for Anticancer Drugs
26. Primary Chemotherapy
27. Abstract OT2-25-01: Irene study: Phase 2 study of Incmga00012 and the oncolytic virus pelareorep in metastatic triple negative breast cancer
28. Abstract P2-12-15: Neoadjuvant liposomal doxorubicin and carboplatin is effective and tolerable for the treatment of early stage triple negative breast cancer
29. Abstract OT1-17-02: A phase II study of pembrolizumab plus fulvestrant in hormone receptor positive, HER-2 negative advanced/metastatic breast cancer patients
30. Immune Checkpoint Inhibitors in Triple Negative Breast Cancer: The Search for the Optimal Biomarker
31. Phase I Trial Design and Methodology
32. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
33. Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer
34. Durable Response to PD1 Inhibitor Pembrolizumab in a Metastatic, Metaplastic Breast Cancer
35. A single-arm phase II trial of palbociclib in combination with tamoxifen as first-line therapy for metastatic hormone receptor-positive breast cancer.
36. 41569 The Parallel of HLA Inherence and Autoimmune Adverse Events of Immunotherapy: A Paradigm for Risk Stratification and Early Detection
37. Polymorphic variants in TSC1 and TSC2 and their association with breast cancer phenotypes
38. Adjuvant Chemotherapy for Early Stage Breast Cancer: Current Trends and Future Directions
39. SARS‐CoV‐2 nosocomial infection: Real‐world results of environmental surface testing from a large tertiary cancer center
40. Abstract OT-32-02: Irene study: Phase 2 study of incmga00012 (retifanlimab)and the oncolytic virus pelareorep in metastatic triple negative breast cancer
41. Abstract PD14-07: Association between biomarkers and response to pembrolizumab in patients with metastatic triple-negative breast cancer (mTNBC): Exploratory analysis from KEYNOTE-086
42. The Decision to Test in Women Receiving Genetic Counseling for BRCA1 and BRCA2 Mutations
43. Environmental Sars-Cov-2 Surface Testing: Low Incidence of Virus Positivity in Outpatient and Inpatient Hematology/Oncology Settings
44. 5-year Update of a Multi Institution Prospective Phase II Hypofractionated Post-Mastectomy Radiation Therapy trial
45. Subjective and Objective Risks of Carrying a BRCA1/2 Mutation in Individuals of Ashkenazi Jewish Descent
46. A genetic variant in a PP2A regulatory subunit encoded by the PPP2R2B gene associates with altered breast cancer risk and recurrence
47. Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial
48. Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy
49. Testing considerations for phosphatidylinositol‐3‐kinase catalytic subunit alpha as an emerging biomarker in advanced breast cancer
50. Reducing Oncologic Disparities by Standardizing Cancer Care
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.